Literature DB >> 16400651

Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.

David M Latini1, Eric P Elkin, Matthew R Cooperberg, Natalia Sadetsky, Janeen Duchane, Peter R Carroll.   

Abstract

BACKGROUND: Few studies of ethnicity and prostate cancer have included Latino men in analyses of baseline clinical characteristics, treatment selection, and disease-free survival (DFS). The present study examines the impact of Latino ethnicity on these parameters in a large, multiinstitutional database of men with prostate cancer.
METHODS: We compared baseline disease characteristics and clinical outcomes for Latino (N = 138), non-Latino White (NLW, N = 5619), and African-American (AA, N = 608) men with localized prostate cancer by using chi-square and ANOVA for baseline variables and survival analysis to examine differences in time to recurrence.
RESULTS: Latino men resembled AA men more than NLW on sociodemographic characteristics. AA men had higher Gleason scores and prostate-specific antigen (PSA) at diagnosis than Latino or NLW men (both P < 0.01). 10% of both Latino and AA men presented with advanced disease (T3b/T4/N+/M+) versus 4% of NLW (P < 0.01). Latino men did not receive different treatments than NLW or AA men after controlling for clinical and demographic factors; however, AA men were more likely to receive external beam radiation (OR = 1.51, 95% confidence interval [CI] = 0.99-2.31) and hormone treatment (OR = 1.56, 95% CI = 1.05-2.32) then NLW men. For prostatectomy patients, 3-year actuarial DFS rates were 83% for NLW men and 86% for Latino men versus 69% for AA men (P < 0.01). After controlling for clinical and sociodemographic variables, AA men were somewhat more likely than NLW to experience disease recurrence after radical prostatectomy (RP) (HR = 1.38, 95% CI = 0.98-1.94, P = 0.06).
CONCLUSIONS: Latinos are more similar to African Americans on sociodemographic characteristics but more similar to NLW on clinical presentation, treatments received, and DFS. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16400651     DOI: 10.1002/cncr.21675

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  A review of cancer in U.S. Hispanic populations.

Authors:  Robert W Haile; Esther M John; A Joan Levine; Victoria K Cortessis; Jennifer B Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L Tucker; Jonine L Bernstein; Thomas E Rohan; Gloria Y F Ho; Melissa L Bondy; Maria Elena Martinez; Linda Cook; Mariana C Stern; Marcia Cruz Correa; Jonelle Wright; Seth J Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R Monroe; Christopher A Haiman; Brian E Henderson; Duncan C Thomas; Paolo Boffetta
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

2.  Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men.

Authors:  Nicholas M Donin; Stacy Loeb; Phillip R Cooper; Kimberly A Roehl; Nikola A Baumann; William J Catalona; Brian T Helfand
Journal:  BJU Int       Date:  2014-07-15       Impact factor: 5.588

3.  Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Authors:  Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

Review 4.  Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap.

Authors:  Daniel A Barocas; David F Penson
Journal:  BJU Int       Date:  2010-06-14       Impact factor: 5.588

5.  Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.

Authors:  Kendra Schwartz; Isaac J Powell; Willie Underwood; Julie George; Cecilia Yee; Mousumi Banerjee
Journal:  Urology       Date:  2009-12       Impact factor: 2.649

6.  Racial variation in the quality of surgical care for prostate cancer.

Authors:  Daniel A Barocas; Darryl T Gray; Jay H Fowke; Nathaniel D Mercaldo; Jeffrey D Blume; Sam S Chang; Michael S Cookson; Joseph A Smith; David F Penson
Journal:  J Urol       Date:  2012-08-16       Impact factor: 7.450

7.  Evaluation of prostate cancer characteristics in four populations worldwide.

Authors:  Charnita M Zeigler-Johnson; Hanna Rennert; R Devi Mittal; Mohamed Jalloh; Rajeev Sachdeva; S Bruce Malkowicz; Anil Mandhani; B Mittal; Serigne M Gueye; Timothy R Rebbeck
Journal:  Can J Urol       Date:  2008-06       Impact factor: 1.344

8.  Prostate cancer risk profiles of Asian-American men: disentangling the effects of immigration status and race/ethnicity.

Authors:  Daphne Y Lichtensztajn; Scarlett Lin Gomez; Weiva Sieh; Benjamin I Chung; Iona Cheng; James D Brooks
Journal:  J Urol       Date:  2013-10-25       Impact factor: 7.450

9.  The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis.

Authors:  Maria C Velasquez; Felix M Chinea; Deukwoo Kwon; Nachiketh Soodana Prakash; Marcelo P Barboza; Mark L Gonzalgo; Chad R Ritch; Alan Pollack; Dipen J Parekh; Sanoj Punnen
Journal:  Urology       Date:  2018-04-06       Impact factor: 2.649

10.  Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.

Authors:  Melanie Mediavilla-Varela; Fabio J Pacheco; Frankis Almaguel; Jossymar Perez; Eva Sahakian; Tracy R Daniels; Lai Sum Leoh; Amelia Padilla; Nathan R Wall; Michael B Lilly; Marino De Leon; Carlos A Casiano
Journal:  Mol Cancer       Date:  2009-08-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.